Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).
about
Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitorsComparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine modelAntifungal peptides: novel therapeutic compounds against emerging pathogensEvaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosisStructure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic PropertiesTreatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.Limitations of caspofungin in the treatment of obstructive pyonephrosis due to Candida glabrata infection.Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats.Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.Pharmacokinetics and safety of intravitreal caspofungin.Human pharmacogenomic variations and their implications for antifungal efficacy.Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis.Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.Serum differentially alters the antifungal properties of echinocandin drugs.Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous modelBioanalysis in drug discovery and development.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.Tissue penetration of antifungal agents.Current perspectives on echinocandin class drugs.Effects of echinocandin preparations on adult rat ventricular cardiomyocytes. Preliminary results of an in vitro studyPreclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species.Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus.Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model.Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.Efficacy of caspofungin against Aspergillus terreus.Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.Cardiac effects of echinocandins after central venous administration in adult rats.Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy.Effects of serum on in vitro susceptibility testing of echinocandinsMethodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice
P2860
Q28343863-15968047-2D1A-46A0-8D21-E3932ACF0645Q28344362-E8EB22DF-A80A-49F4-81CD-1C766831346EQ28369443-0C41160E-BBD2-4F97-9662-FED8A5CF223BQ28379219-572F3422-EE7D-4047-A859-64101585D4CEQ28817906-71F4F56A-CA18-42AC-AC95-CFB41F509AE7Q30319796-F80B3E67-A97A-4FC3-88E2-55D4121696ADQ33253245-0C16143E-E6D2-4EE3-9281-EB26B73920AAQ33757912-E2BC7268-F436-41B2-ADF6-75BF14DECC99Q33805542-C76F3458-42D2-4D8F-AA49-5DA413DBDDAFQ33876423-EA69B78B-F028-456F-8C6D-AA59F4B55541Q33981480-13187A02-D801-40C4-9E80-66972C246057Q34104748-2BE990E4-F3C8-4726-8BCA-8B028A6805C1Q34228214-6CB5BA2C-FCB1-4593-BAAE-EB3BCDE578DCQ34597632-0A243D78-74CE-4A22-86C8-C8828828FD03Q35070838-ED95CA4B-65C0-425E-A9E1-5261C7ACC799Q35270948-6D675920-2120-4032-BD7B-84BDE5DF366BQ35840760-29D9AFD6-93C8-49F0-BD47-328688225E96Q35840860-9DF6E087-284B-4DE8-BCDB-8D65213776FAQ35959489-8F00F102-900F-4CC2-AD3B-870F2FDB6D4DQ36785799-7A412FB1-B0D1-4F7B-AECF-9C251A82674CQ36855961-BAF50859-E1C6-41C2-ABAE-E50670C9FEDEQ36948094-4393FD02-A363-4C0E-8F04-3BFDE5E0087BQ37121115-65AEBF72-3417-4961-80FA-9835CE3C4AD8Q37544911-18315277-BE56-4906-8ECF-6302082BC793Q37554055-94C29703-2FCA-4DD4-A61F-B49174467C54Q37578555-4D935C1A-07B7-4100-BB8C-D7E726091A64Q37720794-F29CDADF-88AE-4860-9864-AA1E058E9FA4Q37720796-802E653B-57BD-495A-995E-8D8FBD82FDDCQ39475635-959F155D-5EB7-4EDE-83C2-3C922500EA3CQ40121744-BBBAF83C-2FC7-44F7-8E7A-B054E1574C98Q40667866-3E116A0D-CDB5-41B3-B5B3-C8C4262E7D2CQ40668303-B01BE417-4622-4E4F-B5CF-D0459CD65EB3Q41907600-2342C680-8CDB-4E34-9BBB-2651DC4D45ECQ42111965-9AABD9B2-3BA9-4C5F-B5D1-A98C9C0AEEEDQ42112398-99D007D8-A895-4521-B556-10A6926BB8A1Q42687352-B4BD10B1-8F37-4366-B3CC-2C1F11DD64E8Q42861062-7A302A39-9C4B-4C4C-A81D-7CCA2C2AA34FQ55511181-3FD1560B-C2ED-4A46-9F59-C933C43878A0Q57175587-7120A28D-AB96-4DC8-A0D8-17E88D53E8F9
P2860
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Preliminary animal pharmacokin ...... gal agent MK-0991 (L-743,872).
@ast
Preliminary animal pharmacokin ...... gal agent MK-0991 (L-743,872).
@en
type
label
Preliminary animal pharmacokin ...... gal agent MK-0991 (L-743,872).
@ast
Preliminary animal pharmacokin ...... gal agent MK-0991 (L-743,872).
@en
prefLabel
Preliminary animal pharmacokin ...... gal agent MK-0991 (L-743,872).
@ast
Preliminary animal pharmacokin ...... gal agent MK-0991 (L-743,872).
@en
P2093
P2860
P356
P1476
Preliminary animal pharmacokin ...... ngal agent MK-0991 (L-743,872)
@en
P2093
F A Bouffard
J F Dropinski
J G Sundelof
R Thompson
P2860
P304
P356
10.1128/AAC.41.11.2339
P407
P577
1997-11-01T00:00:00Z